BridgeBio Pharma (NASDAQ:BBIO), headquartered in Palo Alto, California, is a biopharmaceutical company that focuses on the creation and testing of transformative medications for genetic diseases and cancers. On Friday, October 8th, 2021, BBIO saw a significant hike in options volume, reaching a total call volume of 6,159; over